Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06611176

Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions

Led by Laura Boer · Updated on 2024-12-02

88

Participants Needed

3

Research Sites

74 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Endoscopic submucosal dissection (ESD) is commonly performed for (pre)cancerous lesions in the esophagus. Following ESD, post-procedural chest pain is seen in many patients. Studies have shown that local bupivacaine (BP) into the residual submucosal layer of the resection wound after gastric ESD could reduce post-procedural pain rates effectively. Levobupivacaine (LB) is equipotent to BP regarding analgesic effects, but has a better safety profile. No studies have been performed to evaluate the efficacy of LB after esophageal ESD to reduce pain. Therefore, we want to evaluate the effect on post-procedural pain of local application of LB during esophageal ESD.

CONDITIONS

Official Title

Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients age 18 years at time of consent
  • Visible lesion in the esophagus, minimum diameter of the lesion 20 mm
  • Scheduled for esophageal ESD
  • Informed consent
Not Eligible

You will not qualify if you...

  • Presence of multiple lesions requiring two or more separate endoscopic resections
  • History of esophageal surgery other than fundoplications
  • History of esophageal ablation therapy
  • History of radiotherapy of the esophagus
  • Esophageal varices
  • Prior endoscopic resection in the same area
  • Uncontrolled coagulopathy
  • Severe medical comorbidities precluding endoscopy
  • Allergy to LB or other amide-type local anaesthesia
  • Current regular use of opioids
  • Other aetiology causing pain similar to post-ESD pain
  • Inability to assess pain due to severe psychiatric or neurological disease
  • Insufficient command of Dutch language
  • Brugada syndrome
  • Incapacitated patients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

UMCG

Groningen, Netherlands

Actively Recruiting

2

St Antonius Hospital

Nieuwegein, Netherlands

Actively Recruiting

3

UMCU

Utrecht, Netherlands

Actively Recruiting

Loading map...

Research Team

L

Laura S Boer, Degree of medicine

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here